Novartis will pay up to $400 million in potential additional payments. "Novartis to Buy Myricx Bio for Up to $1.5 Billion," at 0523 GMT, misstated the figure.
Novartis will pay up to $400 million in potential additional payments. "Novartis to Buy Myricx Bio for Up to $1.5 Billion," at 0523 GMT, misstated the figure.
(END) Dow Jones Newswires
July 06, 2026 02:05 ET (06:05 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.
The articles, information, and content displayed on this webpage may
Novartis buys UK biotech Myricx for up to $1.5bn to chase a new cancer-drug class
Novartis commits $1.1B upfront to take Myricx Bio and its next-gen ADC platform
Novartis acquires British start-up Myricx Bio
Patent cliff fuels Novartis' $1.5bn swoop for London biotech
Novartis Scoops up UK Biotech Myricx in $1.5 Billion Cancer Push - Novartis (NYSE:NVS)
Novartis: rileva gruppo biotecnologie Myricx Bio per 1,1 mld $
London's Myricx Bio lands up to $1.5B Novartis exit after raising just $121M — TFN
Novartis rileva Myricx Bio in un’operazione fino a 1,5 miliardi di dollari
Novartis to acquire ADC developer in a deal worth up to $1.5B
Aussie super funds hit the jackpot in $2b UK biotech deal
Novartis will pay $1.1bn upfront and up to $400m in milestones for Myricx Bio, a UK firm developing a novel payload for…
Novartis pays $1.1B upfront (up to $1.5B total) for Myricx Bio, gaining its NMT inhibitor ADC payload platform and two…
The Swiss pharma giant will pay $1.1 billion (CHF883 million) to acquire Myricx Bio, which is developing antibody-drug conjugates…
Novartis has acquired UK biotech Myricx for up to $1.5bn as global drugmakers invest inpromising biotech firms ahead expected…
Novartis acquires Myricx Bio for up to $1.5B to boost its oncology pipeline with a novel next-gen ADC cancer platform. Read more.
(Il Sole 24 Ore Radiocor) - Il colosso farmaceutico svizzero Novartis ha rilevato il gruppo britannico delle biotecnologie Myricx…
